NASDAQ:CASI CASI Pharmaceuticals (CASI) Stock Price, News & Analysis $0.21 0.00 (0.00%) As of 10/2/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsOptions ChainOwnershipSEC Filings About CASI Pharmaceuticals Stock (NASDAQ:CASI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CASI Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.21▼$0.2150-Day Range$0.21▼$0.2152-Week Range$0.21▼$3.09VolumeN/AAverage Volume482,532 shsMarket Capitalization$2.55 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s activities are concentrated primarily in hematology and oncology, with a geographic focus that includes the United States and China. CASI’s commercial portfolio has included EVOMELA (melphalan for injection), an oncology product used as a conditioning treatment before autologous stem-cell transplantation and as palliative therapy for patients with multiple myeloma. Through its China-based operations, the company has also pursued the development and commercialization of innovative cell therapies, including equecabtagene autoleucel, an investigational or regionally approved CAR-T therapy designed to treat certain relapsed or refractory B-cell malignancies. Founded in the United States, CASI has expanded its operations through partnerships, licensing arrangements and subsidiaries serving the Chinese pharmaceutical market. The company is led by Wei-Wu He, who has served as its chairman and chief executive officer, and continues to focus on advancing oncology products through development, regulatory review and commercialization.AI Generated. May Contain Errors. Read More CASI Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks0th Percentile Overall ScoreCASI MarketRank™: CASI Pharmaceuticals scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingCASI Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCASI Pharmaceuticals has received no research coverage in the past 90 days.Read more about CASI Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CASI Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CASI Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCASI Pharmaceuticals has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CASI. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCASI Pharmaceuticals does not currently pay a dividend.Dividend GrowthCASI Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for CASI Pharmaceuticals this week, compared to 1 article on an average week. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CASI Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders21.24% of the stock of CASI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions22.23% of the stock of CASI Pharmaceuticals is held by institutions.Read more about CASI Pharmaceuticals' insider trading history. Receive CASI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CASI Stock News HeadlinesComparing Eloxx Pharmaceuticals (NASDAQ:ELOX) and CASI Pharmaceuticals (NASDAQ:CASI)October 4 at 4:15 AM | americanbankingnews.comCASI Pharmaceuticals stock plunges on Nasdaq delisting noticeFebruary 26, 2026 | za.investing.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.October 4 at 1:00 AM | Behind the Markets (Ad)What Drove CASI Pharmaceuticals' 24% Rise After Hours?February 26, 2026 | msn.comCASI Pharmaceuticals Fails to Renew FOLOTYN Import License in China, Halts SalesJanuary 24, 2026 | theglobeandmail.comCASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated RejectionJanuary 15, 2026 | finanznachrichten.deCASI Pharmaceuticals wins Nasdaq listing extension to February 2026December 23, 2025 | msn.comCASI Pharmaceuticals stock surges after Nasdaq grants listing extensionDecember 23, 2025 | za.investing.comSee More Headlines CASI Stock Analysis - Frequently Asked Questions How have CASI shares performed this year? CASI Pharmaceuticals' stock was trading at $0.85 on January 1st, 2026. Since then, CASI shares have decreased by 75.6% and is now trading at $0.2075. How were CASI Pharmaceuticals' earnings last quarter? CASI Pharmaceuticals Inc. (NASDAQ:CASI) posted its quarterly earnings data on Friday, November, 14th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $0.27. The biotechnology company earned $3.08 million during the quarter. When did CASI Pharmaceuticals' stock split? CASI Pharmaceuticals's stock reverse split before market open on Wednesday, June 1st 2022.The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of CASI Pharmaceuticals? Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CASI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that CASI Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Arista Networks (ANET), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings11/14/2025Today10/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (10m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CASI's financial health is in the Yellow zone, according to TradeSmith. CASI has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CASI CIK1962738 Webwww.casipharmaceuticals.com Phone861065086063Fax301-315-2437Employees180Year Founded1991Profitability EPS (Trailing Twelve Months)($3.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.26 million Net Margins-183.93% Pretax Margin-175.56% Return on EquityN/A Return on Assets-131.54% Debt Debt-to-Equity RatioN/A Current Ratio0.30 Quick Ratio0.24 Sales & Book Value Annual Sales$26.85 million Price / Sales0.10 Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book1.73Miscellaneous Outstanding Shares12,299,000Free Float9,687,000Market Cap$2.55 million OptionableOptionable Beta0.91 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:CASI) was last updated on 10/4/2026 by MarketBeat.com Staff. From Our PartnersThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CASI Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CASI Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CASI Stock Alerts